{"entity":{"id":"nct05170958","kind":"trial","name":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of LBL-024 for Injection in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.","summary":"A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05170958 by Nanjing Leads Biolabs Co.,Ltd, with 396 participants planned, started 2022-01-06 and due to reach its primary completion in 2026-12. Interventions recorded: LBL-024 for Injection.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05170958","url":"https://clinicaltrials.gov/study/NCT05170958"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05170958","phase":"1/2","setting":"A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of LBL-024 in Patients With Advanced Malignant Tumors","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":396,"outcomes":[]},"route":"/trials/nct05170958/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}